Aurobindo Pharma Stock

Aurobindo Pharma EBIT

The EBIT of Aurobindo Pharma (AUROPHARMA.NS) as of Aug 20, 2026 is 49.83 B INR. In the previous year, EBIT was 43.85 B INR — a change of 13.64% (higher).

EBIT

49.83 BINR

YoY

13.64%

Last updated:

In 2026, Aurobindo Pharma's EBIT was 49.83 B INR, a 13.64% increase from the 43.85 B INR EBIT recorded in the previous year.

The Aurobindo Pharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B INR)
Date
EBIT (B INR)
Jan 1, 2024
43.85 base
Jan 1, 2025
49.83 base
Jan 1, 2026 (e)
70.60 base
Jan 1, 2027 (e)
83.25 base
Jan 1, 2028 (e)
92.28 base
Jan 1, 2029 (e)
99.73 base
Jan 1, 2030 (e)
0.00 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (B INR)
2031 est -
2030 est -
2029 est 99.73
2028 est 92.28
2027 est 83.25
2026 est 70.60
2025 49.83
2024 43.85
2023 25.38
2022 33.00
2021 44.19
2020 39.35
2019 33.04
2018 32.47
2017 30.20
2016 28.01
2015 22.79
2014 18.28
2013 6.57
2012 4.13
2011 8.08
2010 6.89
2009 4.27
2008 2.52
2007 2.03
2006 1.05
Access this data via the Eulerpool API

Aurobindo Pharma Revenue

Aurobindo Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
290.02 B INR
43.85 B INR
31.73 B INR
Jan 1, 2025
317.24 B INR
49.83 B INR
34.86 B INR
Jan 1, 2026 (e)
334.73 B INR
70.60 B INR
35.91 B INR
Jan 1, 2027 (e)
394.68 B INR
83.25 B INR
45.12 B INR
Jan 1, 2028 (e)
437.49 B INR
92.28 B INR
51.70 B INR
Jan 1, 2029 (e)
472.79 B INR
99.73 B INR
57.92 B INR
Jan 1, 2030 (e)
233.61 M INR
0.00 INR
0.00 INR
Jan 1, 2031 (e)
317.71 M INR
0.00 INR
0.00 INR

Aurobindo Pharma Margins

Aurobindo Pharma stock margins

The Aurobindo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aurobindo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aurobindo Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
52.90 %
15.12 %
10.94 %
Jan 1, 2025
54.87 %
15.71 %
10.99 %
Jan 1, 2026 (e)
54.87 %
21.09 %
10.73 %
Jan 1, 2027 (e)
54.87 %
21.09 %
11.43 %
Jan 1, 2028 (e)
54.87 %
21.09 %
11.82 %
Jan 1, 2029 (e)
54.87 %
21.09 %
12.25 %
Jan 1, 2030 (e)
54.87 %
0.00 %
0.00 %
Jan 1, 2031 (e)
54.87 %
0.00 %
0.00 %

Aurobindo Pharma Stock analysis

What does Aurobindo Pharma do? Aurobindo Pharma Ltd is a global pharmaceutical company based in India. It was founded in 1986 by P.V. Ramprasad Reddy, K. Nityananda Reddy, and Kambhampati Hari Babu. It has become one of the leading companies in the industry over the past 35 years. The company's business model is based on the production and distribution of generics, active pharmaceutical ingredients, and biosimilars. It operates in several divisions, covering a wide range of products. Aurobindo Pharma's main division is the manufacturing of generics, including both simple generics and complex products like biosimilars. The company also produces a variety of pharmaceutical ingredients used in industries such as pharmacy, cosmetics, and food. In addition, Aurobindo is involved in the production of biosimilars, which are biological drugs that have similar properties to existing biological products. These products have the potential to improve access to life-saving medications and generate significant cost savings. Aurobindo also manufactures products for the veterinary medicine industry, including antibiotics, antiparasitics, and vitamins. The company has also established a strong presence in the American market in recent years through acquisitions and offers a wide range of products. It has also expanded its presence in Europe, Asia, and Africa. In 2020, Aurobindo Pharma played a significant role in combating the COVID-19 pandemic by introducing several medications that can be used to treat the virus, such as hydroxychloroquine and azithromycin for mild to moderate cases. The company has earned a reputation as a leader in the generics and active pharmaceutical ingredient markets and aims to provide high-quality medications at affordable prices, making a positive contribution to global health improvement. Aurobindo Pharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Aurobindo Pharma's EBIT

Aurobindo Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Aurobindo Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Aurobindo Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Aurobindo Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Aurobindo Pharma stock

EBIT of Aurobindo Pharma is 49.83 B INR in 2026.

EBIT of Aurobindo Pharma changed from 43.85 B INR to 49.83 B INR, representing a 13.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Aurobindo Pharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Aurobindo Pharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Aurobindo Pharma

All Key Metrics — Aurobindo Pharma